Outcome measures of disease severity in atopic eczema

被引:156
作者
Charman, C [1 ]
Williams, H [1 ]
机构
[1] Queens Med Ctr, Dept Dermatol, Nottingham NG7 2UH, England
关键词
D O I
10.1001/archderm.136.6.763
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: An essential component of evidence-based medicine is the use of valid and reliable outcome measures in clinical trials. There is much confusion in the field of atopic eczema regarding how to best measure disease severity objectively. Objective: To establish the extent to which existing objective clinical scales for atopic eczema have been tested for validity, reliability, sensitivity to change, and acceptability. Design: An electronic bibliographic search was performed for published data on all currently available named atopic eczema scales. Results: Thirteen scales were identified in total. Data on construct or criterion validity were available for 10 scales. Only 5 scales had been tested for reliability (interobserver variability, intraobserver variability, or internal consistency). Data on responsiveness to change were available for 8 scales. An estimated time to administer the measure had been given for 3 scales. The only severity scale for which published data could be found on validity, reliability, sensitivity, and acceptability testing was the Severity Scoring of Atopic Dermatitis index, although problems occurred with interobserver variation of the index. Conclusion: The rapidly increasing number of severity scales for atopic eczema, many of which have been inadequately tested, has made the interpretation of patient out comes confusing, and comparison of results between studies almost impossible. Consensus among clinicians and researchers on the use of severity scales for atopic eczema should be based on evidence of adequate validity, reliability, sensitivity to change, and ease of use.
引用
收藏
页码:763 / 769
页数:7
相关论文
共 52 条
  • [1] Quality of life measures in psoriasis: a critical appraisal of their quality
    Ashcroft, DM
    Po, ALW
    Williams, HC
    Griffiths, CEM
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1998, 23 (05) : 391 - 398
  • [2] The efficacy, tolerability and safety of a new oral formulation of Sandimmun®-Sandimmun Neoral® in severe refractory atopic dermatitis
    Atakan, N
    Erdem, C
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 1998, 11 (03) : 240 - 246
  • [3] BAHMER FA, 1992, ACTA DERM-VENEREOL, P32
  • [4] QUANTIFICATION OF THE EXTENT AND THE SEVERITY OF ATOPIC-DERMATITIS - THE ADASI SCORE
    BAHMER, FA
    SCHAFER, J
    SCHUBERT, HJ
    [J]. ARCHIVES OF DERMATOLOGY, 1991, 127 (08) : 1239 - 1240
  • [5] Cyclosporine in severe childhood atopic dermatitis: A multicenter study
    BerthJones, J
    Finlay, AY
    Zaki, I
    Tan, B
    Goodyear, H
    LewisJones, S
    Cork, MJ
    Bleehen, SS
    Salek, MS
    Allen, BR
    Friedmann, P
    Harper, J
    Camp, RDR
    Smith, S
    GrahamBrown, RAC
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 34 (06) : 1016 - 1021
  • [6] Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis
    BerthJones, J
    GrahamBrown, BAC
    Marks, B
    Camp, RDR
    English, JSC
    Freeman, K
    Holden, CA
    Rogers, SCF
    Oliwiecki, S
    Friedmann, PS
    LewisJones, MS
    Archer, CB
    Adriaans, B
    Douglas, WS
    Allen, BR
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1997, 136 (01) : 76 - 81
  • [8] EVENING PRIMROSE OIL AND ATOPIC ECZEMA
    BERTHJONES, J
    THOMPSON, J
    GRAHAMBROWN, RAC
    [J]. LANCET, 1995, 345 (8948): : 520 - 520
  • [9] PLACEBO-CONTROLLED TRIAL OF ESSENTIAL FATTY-ACID SUPPLEMENTATION IN ATOPIC-DERMATITIS
    BERTHJONES, J
    GRAHAMBROWN, RAC
    [J]. LANCET, 1993, 341 (8860) : 1557 - 1560
  • [10] A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children
    Boguniewicz, M
    Fiedler, VC
    Raimer, S
    Lawrence, ID
    Leung, DYM
    Hanifin, JM
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 102 (04) : 637 - 644